menu
    • menu
    [{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pepper Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"G1 Therapeutics, Inc","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Pepper Bio","highestDevelopmentStatusID":"6","companyTruncated":"G1 Therapeutics, Inc \/ Pepper Bio"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Deimos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Deimos Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Deimos Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Lerociclib

    Menu

    Lerociclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            G1 Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            G1 Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Deimos Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            G1 Therapeutics and Deimos Sign License for Lerociclib for Radioprotective Uses

                            Details : Through the license agreement, company will gain exclusive rights for the clinical development and commercialization of G1T38 (lerociclib) for radioprotection in the US, Europe etc.

                            Brand Name : G1T38

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : Lerociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Deimos Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            G1 Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            G1 Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pepper Bio

                            Deal Size : $135.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            G1 Therapeutics and Pepper Bio Announce Global License Agreement for Lerociclib

                            Details : Under the terms of the license agreement, Pepper Bio will focus on the clinical development of G1T38 (lerociclib) for the treatment of hepatocellular carcinoma.

                            Brand Name : G1T38

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 01, 2024

                            Lead Product(s) : Lerociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pepper Bio

                            Deal Size : $135.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth